» Articles » PMID: 31368827

Advances in Technologies for Cervical Cancer Detection in Low-resource Settings

Overview
Specialty Molecular Biology
Date 2019 Aug 2
PMID 31368827
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

: Cervical cancer mortality rates remain high in low- and middle-income countries (LMICs) and other medically underserved areas due to challenges with implementation and sustainability of routine screening, accurate diagnosis, and early treatment of preinvasive lesions. : In this review, we first discuss the standard of care for cervical cancer screening and diagnosis in high- and low-resource settings, biomarkers that correlate to cervical precancer and cancer, and needs for new tests. We review technologies for screening and diagnosis with a focus on tests that are already in use in LMICs or have the potential to be adapted for use in LMICs. Finally, we provide perspectives on the next five years of technology development for improved cervical cancer screening and diagnosis in LMICs. : Innovation toward improved molecular and imaging tests is needed to enable effective, affordable see-and-treat approaches to detect and treat cervical precancer in a single visit. Current molecular tests remain too complex and/or costly for widespread use. Especially with imaging tests, decision support may improve performance of new technologies.

Citing Articles

A paper-based HPV E7 oncoprotein assay for cervical precancer detection at the point of care.

Smith C, Paul S, Haney K, Parra S, Bond M, Lopez L Sci Rep. 2025; 15(1):3041.

PMID: 39856147 PMC: 11760965. DOI: 10.1038/s41598-024-79472-2.


Automated analysis of digital medical images in cervical cancer screening: A systematic review.

Ledwaba L, Saidu R, Malila B, Kuhn L, Mutsvangwa T medRxiv. 2024; .

PMID: 39399017 PMC: 11469345. DOI: 10.1101/2024.09.27.24314466.


Optical imaging for screening and early cancer diagnosis in low-resource settings.

Richards-Kortum R, Lorenzoni C, Bagnato V, Schmeler K Nat Rev Bioeng. 2024; 2(1):25-43.

PMID: 39301200 PMC: 11412616. DOI: 10.1038/s44222-023-00135-4.


Usability of a smartphone-compatible, confocal micro-endoscope for cervical cancer screening in resource-limited settings.

Kadama-Makanga P, Semeere A, Laker-Oketta M, Mubiru M, Lukande R, Huchko M BMC Womens Health. 2024; 24(1):483.

PMID: 39223605 PMC: 11367841. DOI: 10.1186/s12905-024-03323-5.


Lightweight Low-Rank Adaptation Vision Transformer Framework for Cervical Cancer Detection and Cervix Type Classification.

Hong Z, Xiong J, Yang H, Mo Y Bioengineering (Basel). 2024; 11(5).

PMID: 38790335 PMC: 11118906. DOI: 10.3390/bioengineering11050468.


References
1.
Mayrand M, Duarte-Franco E, Rodrigues I, Walter S, Hanley J, Ferenczy A . Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357(16):1579-88. DOI: 10.1056/NEJMoa071430. View

2.
Catarino R, Petignat P, Dongui G, Vassilakos P . Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices. World J Clin Oncol. 2015; 6(6):281-90. PMC: 4675913. DOI: 10.5306/wjco.v6.i6.281. View

3.
Nessa A, Wistrand C, Begum S, Thuresson M, Shemer I, Thorsell M . Evaluation of stationary colposcope and the Gynocular, by the Swede score systematic colposcopic system in VIA positive women: a crossover randomized trial. Int J Gynecol Cancer. 2013; 24(2):339-45. PMC: 3921262. DOI: 10.1097/IGC.0000000000000042. View

4.
Castle P, Rodriguez A, Burk R, Herrero R, Wacholder S, Hildesheim A . Long-term persistence of prevalently detected human papillomavirus infections in the absence of detectable cervical precancer and cancer. J Infect Dis. 2011; 203(6):814-22. PMC: 3071125. DOI: 10.1093/infdis/jiq116. View

5.
Franco E . Self-sampling for cervical cancer screening: Empowering women to lead a paradigm change in cancer control. Curr Oncol. 2018; 25(1):e1-e3. PMC: 5832283. DOI: 10.3747/co.25.3969. View